Druck Icon

Eckert & Ziegler AG: Increasing Sales of 28% in the Therapy Segment

Berlin, May 10, 2005. Eckert & Ziegler AG (ISIN DE0005659500), a Berlin-based specialist for radiation related products for the diagnosis and treatment of cancer, increased its sales by 8% to 8.6 million EUR (previous year: 8.0 Mio EUR) in the first quarter. Most of this increase is due to the Therapy segment which grew by 28% to 3.7 million EUR (previous year: 2.9 million EUR), despite delays in the delivery of tumor radiation systems. Profit per share declined in the first quarter to 0.09 EUR (previous year: 0.14 EUR), mainly due dot missing gross margin. The level of liquid funds and money-like securities remained nearly unchanged throughout the period under period, at 7.1 million EUR. For the financial year 2005 the management expects sales of approximately 40 million EUR and an earning per share between 0,50 and 0,80 EUR.

The complete quarterly report I/2005 can be viewed at www.ezag.com.

The Board of Directors